Mexedrone (4-methoxymethcathinone, 4-MMC-methoxy, mexedrine) is a synthetic stimulant of the cathinone chemical class, structurally derived from mephedrone (4-MMC) through replacement of the 4-methyl group with a 4-methoxy group. This single-atom substitution produces a compound with a meaningfully different pharmacological profile: where mephedrone is a potent dopamine and norepinephrine releasing agent with significant entactogenic serotonergic activity, mexedrone is primarily a serotonin releasing agent and monoamine reuptake inhibitor — substantially weaker in its overall potency and with a different qualitative character.
Mexedrone's serotonin-dominant pharmacology (it is approximately 10–20 times weaker than mephedrone in dopamine/noradrenaline reuptake inhibition, while retaining serotonin releasing properties) means the subjective experience is relatively mild by cathinone standards: modest mood lift, mild empathogenic qualities, reduced anxiety, and limited stimulation. Users often describe it as a gentle entactogen with a softer hedonic impact than mephedrone or MDMA analogs, and with correspondingly less compulsive character than potently dopaminergic cathinones.
Despite its milder profile, mexedrone carries the fundamental risks of serotonergic substances: serotonin syndrome risk in combination with MAOIs and other serotonergic agents, and the potential for serotonergic neurotoxicity with heavy repeated use. The serotonin-dominant mechanism also means mexedrone produces typical serotonin-mediated effects including bruxism (jaw clenching), hyperthermia risk in active environments, and the serotonin depletion comedown.
Mexedrone is frequently discussed in the context of combining with other substances to add an entactogenic dimension to a stimulant experience — but this combination use amplifies the serotonergic risk and is not advisable. Its milder subjective profile makes its inherent pharmacological risks easier to underestimate.
Safety at a Glance
High Risk- Serotonin Syndrome is the Primary Risk
- Test Your Substance
- Toxicity: Serotonin Syndrome Risk Mexedrone's serotonin-releasing and reuptake-inhibiting activity makes it a significant contr...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from Mexedrone is a medical emergency primarily involving cardiovascular and n...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
Mexedrone arrives as the mildest possible suggestion of what its more potent cathinone relatives deliver. Within thirty to sixty minutes of ingestion, a faint warmth appears in the chest, and there is a subtle lift in mood that could be attributed to expectation as easily as to pharmacology. The stimulation, if it can properly be called that, is barely perceptible: a slight increase in alertness, a marginally improved disposition toward social interaction, and a whisper of the empathogenic warmth that characterizes more active entactogens.
At what passes for the peak, typically reached around one to two hours in, mexedrone offers a gentle, muted version of the cathinone experience. There is a mild sociability, a slight desire to engage in conversation and connect with others. Music may sound fractionally better. Touch may feel marginally more pleasant. But these effects are gossamer-thin, easily overwhelmed by mood, setting, or the simple passage of time. The euphoria, if present, is the emotional equivalent of a slightly warmer than usual breeze: noticeable if you are paying attention, negligible if you are not.
Physically, mexedrone is remarkably gentle. Heart rate may increase slightly, and appetite may diminish, but the standard cathinone repertoire of jaw clenching, sweating, vasoconstriction, and temperature spikes is largely absent. The body feels comfortable and unperturbed. This mildness is a double-edged quality: it makes the substance physically safe and well-tolerated but also contributes to the perception that it does not do enough to justify its existence.
The effects, such as they are, taper over two to four hours. The comedown is essentially nonexistent, a seamless return to baseline that is difficult to pinpoint temporally. There is no crash, no emotional deficit, no residual stimulation. Sleep comes at its usual time. The following day is indistinguishable from any other. The overall impression of mexedrone is one of profound understatement. It is a substance that seems to be trying very hard not to be noticed, and it largely succeeds in this endeavor. Users seeking any meaningful psychoactive effect are likely to come away with the sense of having gone to considerable effort for negligible returns.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(10)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Cognitive(10)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
Mexedrone acts as a serotonin releasing agent and reuptake inhibitor for all three primary monoamine transporters (SERT, DAT, NET), but with a markedly different potency profile compared to mephedrone:
- SERT (serotonin): Primary activity; serotonin releasing and reuptake inhibition
- DAT (dopamine): Significantly weaker than mephedrone; approximately 10–20x less potent in dopamine/noradrenaline reuptake inhibition
- NET (norepinephrine): Weaker than mephedrone
The methoxy substitution at the 4-position — replacing the methyl group of mephedrone with a methoxy group — produces this shift in transporter selectivity. The methoxy-substituted ring system reduces the catechol-type activity that supports catecholamine transporter binding while preserving serotonergic activity.
Pharmacological Character
The resulting pharmacological profile — serotonin-dominant, with limited dopaminergic activity — places mexedrone closer to an entactogen/empathogen than a typical stimulant. This contrasts sharply with mephedrone (despite the structural similarity) and explains the qualitatively different subjective experience reported by users: more emotional/empathogenic, less stimulant/euphoric.
Comparison with Mephedrone
Despite structural similarity (4-methyl vs. 4-methoxy), mexedrone and mephedrone have meaningfully different pharmacologies. Mephedrone is among the most potently addictive cathinones. Mexedrone's lower dopaminergic potency corresponds to lower observed addiction liability — though serotonergic risks remain.
Detection Methods
Standard Drug Panel Inclusion
Mexedrone is a substituted cathinone (synthetic cathinone) that is not included on standard 5-panel or 10-panel immunoassay drug screens. Some extended panels (particularly those marketed for "bath salts" detection) may include cross-reactive antibodies for the cathinone class, but coverage is inconsistent. The structural relationship to amphetamine means some cathinones trigger the amphetamine channel on immunoassays, but this is compound-specific and unreliable for Mexedrone.
Urine Detection
Mexedrone and its metabolites can typically be detected in urine for 2 to 4 days following a single dose. Repeated or binge-pattern use may extend this window to 5 or more days. Primary metabolic pathways involve reduction of the beta-keto group, N-dealkylation, and hydroxylation. The resulting metabolites are excreted renally, often as glucuronide or sulfate conjugates.
Blood and Saliva Detection
Blood detection windows for Mexedrone range from 12 to 48 hours depending on dose and individual metabolism. Plasma concentrations decline rapidly due to extensive distribution into tissues. Oral fluid testing can detect Mexedrone for approximately 24 to 48 hours but is not commonly deployed for synthetic cathinones outside of specialized forensic settings.
Hair Follicle Detection
Hair analysis can detect synthetic cathinones including Mexedrone for up to 90 days. Incorporation into the hair shaft follows standard pharmacokinetic principles for basic amines. However, most commercial hair testing panels do not specifically target Mexedrone, requiring custom LC-MS/MS methods with appropriate reference standards.
Confirmatory Testing
Definitive identification of Mexedrone requires instrumental analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for synthetic cathinones due to their thermal lability, which can cause degradation during gas chromatography. GC-MS remains usable but may require derivatization for optimal sensitivity. Reference standards specific to Mexedrone are necessary for quantitative confirmation.
Reagent Testing
Marquis reagent typically produces no reaction or a faint yellow-orange color with Mexedrone. Mecke reagent may show no significant color change. Mandelin reagent can produce a yellow to brown reaction. The lack of strong, characteristic color reactions with common reagents makes cathinone identification by reagent testing alone unreliable. A combination of Marquis, Mecke, Mandelin, and Simon's reagents can help rule out other substance classes but cannot positively confirm Mexedrone.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Development
Mexedrone is a structural modification of mephedrone (4-methylmethcathinone), itself one of the most commercially significant cathinone NPS. The methoxy modification was introduced as part of the structural modification strategy that followed regulatory controls on mephedrone in 2010 in the UK and subsequently elsewhere.
Market Emergence
Mexedrone appeared in drug markets in 2015–2016, identified in forensic drug databases in Europe and documented in early warning system reports. It was sold as a research chemical and attracted some use among people seeking mephedrone-like or MDMA-like experiences.
Pharmacological Significance
Mexedrone is pharmacologically interesting because it demonstrates how a single structural modification (methyl to methoxy) can fundamentally shift the pharmacological profile of a cathinone. This makes it useful for mechanistic studies examining the structural determinants of serotonergic vs. dopaminergic selectivity in cathinone-class compounds.
Regulatory Status
Mexedrone is controlled in the UK, numerous EU member states, and other jurisdictions. In the US, analog scheduling applies. Its regulatory status reflects the widespread scheduling of cathinones following the NPS crisis of the 2010s.
Harm Reduction
Serotonin Syndrome is the Primary Risk
Unlike potently dopaminergic cathinones where compulsive use is the headline concern, mexedrone's principal harm is serotonin-related. Avoiding MAOIs and other serotonergic agents is the most important harm reduction step.
Test Your Substance
Reagent testing to confirm compound class:
Do Not Underestimate Serotonergic Risk
The relatively mild subjective profile of mexedrone can lead to underestimation of its serotonergic risks. The absence of intense dopaminergic stimulation does not mean the compound is low-risk — the serotonin syndrome risk profile is not correlated with subjective intensity.
Space Use
As with other serotonergic substances, space between uses allows neurobiological recovery. Frequent use increases neurotoxic risk.
Avoid Combination Use
Mexedrone may be sought as an "add-on" entactogenic component in multi-drug sessions. This combination use compounds serotonergic risk without meaningful harm reduction benefit.
Dangerous Combinations
- MAOIs: Absolutely contraindicated
- Other entactogens: Additive serotonin syndrome risk
- Stimulants: Additional cardiovascular effects
- Tramadol: Serotonin syndrome risk
Toxicity & Safety
Serotonin Syndrome Risk
Mexedrone's serotonin-releasing and reuptake-inhibiting activity makes it a significant contributor to serotonin syndrome risk in combination with MAOIs. This combination is absolutely contraindicated. Caution is also warranted in combination with SSRIs, SNRIs, other serotonin releasers, lithium, and tramadol.
Cardiovascular Effects
While less potent than mephedrone in dopaminergic terms, mexedrone still produces cardiovascular stimulation via norepinephrine and dopamine activity. Heart rate and blood pressure elevation occur, though generally less pronounced than with more potently dopaminergic cathinones.
Neurotoxicity
The serotonergic mechanism creates the potential for serotonergic neurotoxicity analogous to that associated with MDMA with heavy, frequent use. This risk is poorly characterized for mexedrone specifically.
Bruxism
Serotonin-releasing entactogens characteristically produce bruxism (jaw clenching and teeth grinding), which can cause dental damage with frequent use.
Hyperthermia
Risk of hyperthermia exists, particularly in active environments, through serotonergic mechanisms.
Drug Interactions
- MAOIs: Absolutely contraindicated — serotonin syndrome risk
- Other serotonergic agents: Additive toxicity
- Other stimulants: Additional cardiovascular risk
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from Mexedrone is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Mexedrone is not a controlled substance in most countries, meaning it is ostensibly legal to possess and distribute. However, the sale for human consumption or the use for non-medical or research purposes could be prosecuted as crimes under an analogue law.
Brazil:** As of September 7, 2018, all cathinone analogues are controlled substances considered illegal to possess, use and distribute. This was made possible due to a blanket ban law appended to Portaria SVS/MS nº 344.
Sweden: Mexedrone is a controlled substance and is therefore illegal to import, produce, sell or possess.
Switzerland: Mexedrone is a controlled substance specifically named under Verzeichnis E.
United Kingdom:** It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
Stimulant
Substituted cathinone
Mephedrone
Mexedrone (Wikipedia)
Mexedrone (Isomer Design)
Discussion
Mexedrone (Bluelight)
Experience Reports (1)
Tips (4)
If you snort Mexedrone, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
Have a landing plan for the Mexedrone comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
Start low with Mexedrone and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Do not combine Mexedrone with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Mexedrone
PubChem compound page for Mexedrone (CID: 129318262)
pubchem - Mexedrone - TripSit Factsheet
TripSit factsheet for Mexedrone
tripsit - Mexedrone - Wikipedia
Wikipedia article on Mexedrone
wikipedia